Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jakub Szymczyk

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Biomedicines|July 29, 2023
FGF1 Protects MCF-7 Cells against Taltobulin through Both the MEKs/ERKs and PI3K/AKT Signaling PathwayJakub Szymczyk, Aleksandra Czyrek, Jacek Otlewski, et al.
International Journal of Biological Macromolecules|July 25, 2022
Cyclic and dimeric fibroblast growth factor 2 variants with high biomedical potentialMateusz A Krzyscik, Łukasz Opaliński, Jakub Szymczyk, et al.
Frontiers in Oncology|October 24, 2022
FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT <i>via</i> two independent mechanismsJakub Szymczyk, Martyna Sochacka, Patryk Chudy, et al.
Cancers|November 27, 2021
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug ResistanceJakub Szymczyk, Katarzyna Dominika Sluzalska, Izabela Materla, et al.
Frontiers in Pharmacology|December 6, 2021
Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting AgentKarolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, et al.
Frontiers in Pharmacology|September 27, 2024
Overcoming drug resistance of cancer cells by targeting the FGF1/FGFR1 axis with honokiol or FGF ligand trapJakub Szymczyk, Martyna Sochacka, Martyna Biadun, et al.
International Journal of Molecular Sciences|May 12, 2018
High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1Łukasz Opaliński, Jakub Szymczyk, Martyna Szczepara, et al.
Molecular Pharmaceutics|April 7, 2022
Drug Conjugation via Maleimide-Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 PeptibodiesKarolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, et al.
Cell Communication and Signaling : CCS|May 3, 2020
FHF1 is a bona fide fibroblast growth factor that activates cellular signaling in FGFR-dependent mannerMartyna Sochacka, Lukasz Opalinski, Jakub Szymczyk, et al.
Cellular and Molecular Life Sciences : CMLS|October 2, 2023
Intracellular FGF1 protects cells from apoptosis through direct interaction with p53Agata Lampart, Daniel Krowarsch, Martyna Biadun, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Biomedicines|July 29, 2023
FGF1 Protects MCF-7 Cells against Taltobulin through Both the MEKs/ERKs and PI3K/AKT Signaling PathwayJakub Szymczyk, Aleksandra Czyrek, Jacek Otlewski, et al.
International Journal of Biological Macromolecules|July 25, 2022
Cyclic and dimeric fibroblast growth factor 2 variants with high biomedical potentialMateusz A Krzyscik, Łukasz Opaliński, Jakub Szymczyk, et al.
Frontiers in Oncology|October 24, 2022
FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT <i>via</i> two independent mechanismsJakub Szymczyk, Martyna Sochacka, Patryk Chudy, et al.
Cancers|November 27, 2021
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug ResistanceJakub Szymczyk, Katarzyna Dominika Sluzalska, Izabela Materla, et al.
Frontiers in Pharmacology|December 6, 2021
Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting AgentKarolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, et al.
Frontiers in Pharmacology|September 27, 2024
Overcoming drug resistance of cancer cells by targeting the FGF1/FGFR1 axis with honokiol or FGF ligand trapJakub Szymczyk, Martyna Sochacka, Martyna Biadun, et al.
International Journal of Molecular Sciences|May 12, 2018
High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1Łukasz Opaliński, Jakub Szymczyk, Martyna Szczepara, et al.
Molecular Pharmaceutics|April 7, 2022
Drug Conjugation via Maleimide-Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 PeptibodiesKarolina Jendryczko, Jakub Rzeszotko, Mateusz Adam Krzyscik, et al.
Cell Communication and Signaling : CCS|May 3, 2020
FHF1 is a bona fide fibroblast growth factor that activates cellular signaling in FGFR-dependent mannerMartyna Sochacka, Lukasz Opalinski, Jakub Szymczyk, et al.
Cellular and Molecular Life Sciences : CMLS|October 2, 2023
Intracellular FGF1 protects cells from apoptosis through direct interaction with p53Agata Lampart, Daniel Krowarsch, Martyna Biadun, et al.
Pageof 2